Adam Gridley - President, Chief Executive Officer, Director of Histogenics Corporation

Person placeholder

Adam Gridley

President, Chief Executive Officer, Director since 2014

Total compensation: $785,555
Age: 45

Adam Gridley is a President, Chief Executive Officer, Director of Histogenics Corporation. Mr. Gridley previously served from October 2012 until May 2014 as Senior Vice President of Technical Operations at Merz North America, Inc., the North American business unit of Merz, Inc., a privately-held pharmaceuticals company. From September 2011 to October 2012, he was Senior Vice President, Operations & Product Development responsible for global research and development and manufacturing for Merz Aesthetics, Inc., a global business unit of Merz, Inc., and from July 2010 to September 2011, Mr. Gridley held the position of Senior Vice President, Product Development at Merz. From September 2008 to July 2010, Mr. Gridley was Senior Vice President, Corporate Development for BioForm Medical, Inc., a publicly-traded company acquired by Merz, Inc. Mr. Gridley holds a B.S. and an M.B.A. from the University of Denver.

Histogenics Corporation logo

Histogenics Corporation, a regenerative medicine company, focuses on developing and commercializing products in the musculoskeletal segment of the marketplace in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. It has an exclusive channel collaboration agreement with Intrexon Corporation for the development and commercialization of allogeneic genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans. Histogenics Corporation was founded in 2000 and is headquartered in Waltham, Massachusetts.

  • Histogenics Corporation, 830 Winter Street, Waltham 02451, United States
  • histogenics.com
  • 781-547-7900